Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 08, 2015 08:00 ET | Source: Aceragen, Inc.

Idera Pharmaceuticals Enters Into a Strategic Clinical Research Alliance With MD Anderson Cancer Center to Advance Clinical Development of Intratumoral TLR9 Agonist in Combination With Checkpoint Inhibitors

- Intratumoral TLR9 Agonist Provides a Novel Approach to Immuno-Oncology - - First Clinical Trial of IMO-2125 and Checkpoint Inhibitors to be Initiated 2H 2015 - CAMBRIDGE, Mass. and EXTON, Pa.,...
May 27, 2015 09:00 ET | Source: Aceragen, Inc.

Idera to Present at Two June Investor Healthcare Conferences

CAMBRIDGE, Ma. and EXTON, Pa., May 27, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics...
May 18, 2015 08:30 ET | Source: Aceragen, Inc.

Idera Pharmaceuticals Provides Development Update on IMO-9200, an Antagonist of Toll-like Receptors

Company Completed Phase 1 Trial in Healthy Subjects Which Demonstrated IMO-9200 Safe and Well-tolerated Across All Dose Regimens Pre-Clinical Data Supporting IMO-9200 as an Oral Therapeutic Option...
May 11, 2015 07:30 ET | Source: Aceragen, Inc.

Idera Pharmaceuticals Reports First Quarter 2015 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass. and EXTON, Pa., May 11, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and...
April 13, 2015 09:00 ET | Source: Aceragen, Inc.

Idera to Present at the 14th Annual Needham Healthcare Conference

CAMBRIDGE, Mass. and EXTON, Pa., April 13, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA...
April 01, 2015 08:30 ET | Source: Aceragen, Inc.

Idera Announces FDA Orphan Drug Designation for IMO-8400 for the Treatment of Diffuse Large B-Cell Lymphoma

CAMBRIDGE, Mass. and EXTON, Pa., April 1, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and...
March 12, 2015 08:15 ET | Source: Aceragen, Inc.

Idera Pharmaceuticals Reports Fourth Quarter and Year End 2014 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass. and EXTON, Pa., March 12, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and...
February 23, 2015 12:00 ET | Source: Aceragen, Inc.

Idera to Present at Two Upcoming Investor Healthcare Conferences

CAMBRIDGE, Mass. and EXTON, Pa., Feb. 23, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA...
February 19, 2015 15:21 ET | Source: Aceragen, Inc.

Idera Pharmaceuticals Announces Closing of Public Offering of Common Stock

CAMBRIDGE, Mass. and EXTON, Pa., Feb. 19, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA) ("Idera" or the "Company") today announced the closing of its previously announced...
February 13, 2015 08:30 ET | Source: Aceragen, Inc.

Idera Pharmaceuticals Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass. and EXTON, Pa., Feb. 13, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA) ("Idera" or the "Company") today announced the pricing of an underwritten public offering...